|
Editorial
In-Vitro
v/s In-Vivo
On the issue of stability/disintegration and consequent improper
bioavailability of rifampicin in FDCs, an industry-academia rift
has emerged ever since NIPER and L M College of Pharmacy published
their findings.
Edit
Article
The
Indian Pharmaceutical Industry: Beyond 2005
Going by the industry trends, post 2005, Indian companies would
be research outfits for MNCs or powerful players in niche segments
with unmatchable price competitiveness, says Rajiv Kshirsagar
|
